The  ||| S:0 E:4 ||| DT
chemokine  ||| S:4 E:14 ||| JJ
system  ||| S:14 E:21 ||| NN
and  ||| S:21 E:25 ||| CC
its  ||| S:25 E:29 ||| PRP$
contribution  ||| S:29 E:42 ||| NN
to  ||| S:42 E:45 ||| TO
leukemogenesis  ||| S:45 E:60 ||| VB
and  ||| S:60 E:64 ||| CC
treatment  ||| S:64 E:74 ||| NN
responsiveness  ||| S:74 E:89 ||| NN
in  ||| S:89 E:92 ||| IN
patients  ||| S:92 E:101 ||| NNS
with  ||| S:101 E:106 ||| IN
acute  ||| S:106 E:112 ||| JJ
myeloid  ||| S:112 E:120 ||| NNS
leukemia  ||| S:120 E:129 ||| VBP
The  ||| S:129 E:133 ||| DT
chemokine  ||| S:133 E:143 ||| JJ
family  ||| S:143 E:150 ||| NN
consists  ||| S:150 E:159 ||| VBZ
of  ||| S:159 E:162 ||| IN
approximately  ||| S:162 E:176 ||| RB
50  ||| S:176 E:179 ||| CD
small  ||| S:179 E:185 ||| JJ
( ||| S:185 E:186 ||| -LRB-
8-14  ||| S:186 E:191 ||| NNP
kDa ||| S:191 E:194 ||| NNP
) ||| S:194 E:195 ||| -RRB-
,  ||| S:195 E:197 ||| ,
basic  ||| S:197 E:203 ||| JJ
proteins  ||| S:203 E:212 ||| NNS
that  ||| S:212 E:217 ||| WDT
are  ||| S:217 E:221 ||| VBP
expressed  ||| S:221 E:231 ||| VBN
and  ||| S:231 E:235 ||| CC
released  ||| S:235 E:244 ||| VBN
by  ||| S:244 E:247 ||| IN
a  ||| S:247 E:249 ||| DT
wide  ||| S:249 E:254 ||| JJ
range  ||| S:254 E:260 ||| NN
of  ||| S:260 E:263 ||| IN
normal  ||| S:263 E:270 ||| JJ
and  ||| S:270 E:274 ||| CC
malignant  ||| S:274 E:284 ||| JJ
cells ||| S:284 E:289 ||| NNS
.  ||| S:289 E:291 ||| .
Most  ||| S:291 E:296 ||| RBS
chemokines  ||| S:296 E:307 ||| JJ
act  ||| S:307 E:311 ||| NN
through  ||| S:311 E:319 ||| IN
heptahelical  ||| S:319 E:332 ||| FW
transmembrane  ||| S:332 E:346 ||| FW
G  ||| S:346 E:348 ||| FW
protein-  ||| S:348 E:357 ||| FW
coupled  ||| S:357 E:365 ||| FW
receptors ||| S:365 E:374 ||| FW
.  ||| S:374 E:376 ||| .
Based  ||| S:376 E:382 ||| VBN
on  ||| S:382 E:385 ||| IN
their  ||| S:385 E:391 ||| PRP$
molecular  ||| S:391 E:401 ||| JJ
structure  ||| S:401 E:411 ||| NN
these  ||| S:411 E:417 ||| DT
cytokines  ||| S:417 E:427 ||| NNS
are  ||| S:427 E:431 ||| VBP
divided  ||| S:431 E:439 ||| VBN
into  ||| S:439 E:444 ||| IN
the  ||| S:444 E:448 ||| DT
two  ||| S:448 E:452 ||| CD
major  ||| S:452 E:458 ||| JJ
subgroups  ||| S:458 E:468 ||| JJ
CCL  ||| S:468 E:472 ||| NNP
and  ||| S:472 E:476 ||| CC
CXCL  ||| S:476 E:481 ||| NNP
chemokines  ||| S:481 E:492 ||| NN
that  ||| S:492 E:497 ||| IN
bind  ||| S:497 E:502 ||| NN
to  ||| S:502 E:505 ||| TO
CCR  ||| S:505 E:509 ||| NNP
or  ||| S:509 E:512 ||| CC
CXCR  ||| S:512 E:517 ||| NNP
receptors  ||| S:517 E:527 ||| VBD
respectively ||| S:527 E:539 ||| RB
.  ||| S:539 E:541 ||| .
Primary  ||| S:541 E:549 ||| JJ
human  ||| S:549 E:555 ||| JJ
acute  ||| S:555 E:561 ||| JJ
myelogenous  ||| S:561 E:573 ||| JJ
leukemia  ||| S:573 E:582 ||| NN
( ||| S:582 E:583 ||| -LRB-
AML ||| S:583 E:586 ||| NNP
)  ||| S:586 E:588 ||| -RRB-
cells  ||| S:588 E:594 ||| NNS
show  ||| S:594 E:599 ||| VBP
constitutive  ||| S:599 E:612 ||| JJ
release  ||| S:612 E:620 ||| NN
of  ||| S:620 E:623 ||| IN
a  ||| S:623 E:625 ||| DT
wide  ||| S:625 E:630 ||| JJ
range  ||| S:630 E:636 ||| NN
of  ||| S:636 E:639 ||| IN
chemokines ||| S:639 E:649 ||| NN
,  ||| S:649 E:651 ||| ,
but  ||| S:651 E:655 ||| CC
the  ||| S:655 E:659 ||| DT
chemokine  ||| S:659 E:669 ||| JJ
release  ||| S:669 E:677 ||| NN
profile  ||| S:677 E:685 ||| NN
differs  ||| S:685 E:693 ||| VBZ
between  ||| S:693 E:701 ||| IN
patients ||| S:701 E:709 ||| NNS
.  ||| S:709 E:711 ||| .
Among  ||| S:711 E:717 ||| IN
the  ||| S:717 E:721 ||| DT
commonly  ||| S:721 E:730 ||| RB
expressed  ||| S:730 E:740 ||| VBN
chemokines  ||| S:740 E:751 ||| NNS
are  ||| S:751 E:755 ||| VBP
proangiogenic  ||| S:755 E:769 ||| JJ
CXCL8 ||| S:769 E:774 ||| NN
,  ||| S:774 E:776 ||| ,
antiangiogenic  ||| S:776 E:791 ||| CD
CXCL4 ||| S:791 E:796 ||| CD
/ ||| S:796 E:797 ||| CD
9-11  ||| S:797 E:802 ||| CD
and  ||| S:802 E:806 ||| CC
several  ||| S:806 E:814 ||| JJ
leukocyte-chemotactic  ||| S:814 E:836 ||| JJ
chemokines ||| S:836 E:846 ||| NN
.  ||| S:846 E:848 ||| .
Systemic  ||| S:848 E:857 ||| JJ
serum  ||| S:857 E:863 ||| JJ
levels  ||| S:863 E:870 ||| NNS
of  ||| S:870 E:873 ||| IN
leukocyte-chemotactic  ||| S:873 E:895 ||| JJ
chemokines  ||| S:895 E:906 ||| NNS
depend  ||| S:906 E:913 ||| VBP
both  ||| S:913 E:918 ||| DT
on  ||| S:918 E:921 ||| IN
patient  ||| S:921 E:929 ||| JJ
age ||| S:929 E:932 ||| NN
,  ||| S:932 E:934 ||| ,
disease  ||| S:934 E:942 ||| NN
status ||| S:942 E:948 ||| NN
,  ||| S:948 E:950 ||| ,
the  ||| S:950 E:954 ||| DT
chemotherapy  ||| S:954 E:967 ||| JJ
regimen  ||| S:967 E:975 ||| NN
and  ||| S:975 E:979 ||| CC
development  ||| S:979 E:991 ||| NN
of  ||| S:991 E:994 ||| IN
complicating  ||| S:994 E:1007 ||| JJ
infections ||| S:1007 E:1017 ||| NNS
.  ||| S:1017 E:1019 ||| .
The  ||| S:1019 E:1023 ||| DT
local  ||| S:1023 E:1029 ||| JJ
chemokine  ||| S:1029 E:1039 ||| JJ
network  ||| S:1039 E:1047 ||| NN
in  ||| S:1047 E:1050 ||| IN
human  ||| S:1050 E:1056 ||| JJ
AML  ||| S:1056 E:1060 ||| NNP
is  ||| S:1060 E:1063 ||| VBZ
probably  ||| S:1063 E:1072 ||| RB
further  ||| S:1072 E:1080 ||| JJ
modulated  ||| S:1080 E:1090 ||| NN
by  ||| S:1090 E:1093 ||| IN
the  ||| S:1093 E:1097 ||| DT
hypoxic  ||| S:1097 E:1105 ||| JJ
bone  ||| S:1105 E:1110 ||| NN
marrow  ||| S:1110 E:1117 ||| NN
microenvironment  ||| S:1117 E:1134 ||| NNS
and  ||| S:1134 E:1138 ||| CC
the  ||| S:1138 E:1142 ||| DT
local  ||| S:1142 E:1148 ||| JJ
release  ||| S:1148 E:1156 ||| NN
of  ||| S:1156 E:1159 ||| IN
chemokines  ||| S:1159 E:1170 ||| NN
by  ||| S:1170 E:1173 ||| IN
nonleukemic  ||| S:1173 E:1185 ||| JJ
bone  ||| S:1185 E:1190 ||| NN
marrow  ||| S:1190 E:1197 ||| NN
stromal  ||| S:1197 E:1205 ||| NN
cells ||| S:1205 E:1210 ||| NNS
.  ||| S:1210 E:1212 ||| .
Usually  ||| S:1212 E:1220 ||| RB
primary  ||| S:1220 E:1228 ||| JJ
AML  ||| S:1228 E:1232 ||| NN
cells  ||| S:1232 E:1238 ||| NNS
also  ||| S:1238 E:1243 ||| RB
express  ||| S:1243 E:1251 ||| VB
several  ||| S:1251 E:1259 ||| JJ
chemokine  ||| S:1259 E:1269 ||| JJ
receptors ||| S:1269 E:1278 ||| NNS
.  ||| S:1278 E:1280 ||| .
Specific  ||| S:1280 E:1289 ||| JJ
chemokine  ||| S:1289 E:1299 ||| JJ
inhibitors  ||| S:1299 E:1310 ||| NNS
are  ||| S:1310 E:1314 ||| VBP
now  ||| S:1314 E:1318 ||| RB
being  ||| S:1318 E:1324 ||| VBG
developed ||| S:1324 E:1333 ||| VBN
,  ||| S:1333 E:1335 ||| ,
including  ||| S:1335 E:1345 ||| VBG
chemokine-neutralizing  ||| S:1345 E:1368 ||| JJ
or  ||| S:1368 E:1371 ||| CC
receptor-blocking  ||| S:1371 E:1389 ||| JJ
antibodies ||| S:1389 E:1399 ||| NNS
,  ||| S:1399 E:1401 ||| ,
antisense  ||| S:1401 E:1411 ||| JJ
strategies ||| S:1411 E:1421 ||| NNS
,  ||| S:1421 E:1423 ||| ,
receptor-blocking  ||| S:1423 E:1441 ||| JJ
small  ||| S:1441 E:1447 ||| JJ
molecules  ||| S:1447 E:1457 ||| NNS
or  ||| S:1457 E:1460 ||| CC
inhibitors  ||| S:1460 E:1471 ||| NN
of  ||| S:1471 E:1474 ||| IN
downstream  ||| S:1474 E:1485 ||| JJ
signaling ||| S:1485 E:1494 ||| NN
.  ||| S:1494 E:1496 ||| .
The  ||| S:1496 E:1500 ||| DT
use  ||| S:1500 E:1504 ||| NN
of  ||| S:1504 E:1507 ||| IN
CXCR4-antagonists  ||| S:1507 E:1525 ||| CD
for  ||| S:1525 E:1529 ||| IN
mobilization  ||| S:1529 E:1542 ||| NN
of  ||| S:1542 E:1545 ||| IN
peripheral  ||| S:1545 E:1556 ||| JJ
blood  ||| S:1556 E:1562 ||| NN
stem  ||| S:1562 E:1567 ||| NN
cells  ||| S:1567 E:1573 ||| NNS
has  ||| S:1573 E:1577 ||| VBZ
been  ||| S:1577 E:1582 ||| VBN
documented  ||| S:1582 E:1593 ||| VBN
in  ||| S:1593 E:1596 ||| IN
several  ||| S:1596 E:1604 ||| JJ
clinical  ||| S:1604 E:1613 ||| JJ
studies ||| S:1613 E:1620 ||| NNS
.  ||| S:1620 E:1622 ||| .
Although  ||| S:1622 E:1631 ||| IN
animal  ||| S:1631 E:1638 ||| JJ
studies  ||| S:1638 E:1646 ||| NNS
suggest  ||| S:1646 E:1654 ||| VBP
that  ||| S:1654 E:1659 ||| IN
chemokine  ||| S:1659 E:1669 ||| JJ
inhibition  ||| S:1669 E:1680 ||| NNS
also  ||| S:1680 E:1685 ||| RB
may  ||| S:1685 E:1689 ||| MD
become  ||| S:1689 E:1696 ||| VB
useful  ||| S:1696 E:1703 ||| JJ
in  ||| S:1703 E:1706 ||| IN
the  ||| S:1706 E:1710 ||| DT
treatment  ||| S:1710 E:1720 ||| NN
of  ||| S:1720 E:1723 ||| IN
graft  ||| S:1723 E:1729 ||| FW
versus  ||| S:1729 E:1736 ||| FW
host  ||| S:1736 E:1741 ||| NN
disease ||| S:1741 E:1748 ||| NN
,  ||| S:1748 E:1750 ||| ,
the  ||| S:1750 E:1754 ||| DT
possible  ||| S:1754 E:1763 ||| JJ
use  ||| S:1763 E:1767 ||| NN
of  ||| S:1767 E:1770 ||| IN
chemokine-targeting  ||| S:1770 E:1790 ||| JJ
therapy  ||| S:1790 E:1798 ||| NN
for  ||| S:1798 E:1802 ||| IN
other  ||| S:1802 E:1808 ||| JJ
indications  ||| S:1808 E:1820 ||| NNS
than  ||| S:1820 E:1825 ||| IN
stem  ||| S:1825 E:1830 ||| JJ
cell  ||| S:1830 E:1835 ||| NN
mobilization  ||| S:1835 E:1848 ||| NN
requires  ||| S:1848 E:1857 ||| VBZ
further  ||| S:1857 E:1865 ||| JJ
studies ||| S:1865 E:1872 ||| NNS
.  ||| S:1872 E:1874 ||| .
